Our results suggest that risk-score analysis from the DE profile of CLDN7-related immunomodulatory genes can stratify the risk groups, and the discovery of intuitive expression of CLDN7 in BC tissues may improve the validation of BC prognosis. The gene discussed is CLDN7; the disease is breast cancer.